1. Home
  2. RGEN vs ROIV Comparison

RGEN vs ROIV Comparison

Compare RGEN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$164.19

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$22.11

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGEN
ROIV
Founded
1981
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
14.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RGEN
ROIV
Price
$164.19
$22.11
Analyst Decision
Buy
Strong Buy
Analyst Count
10
8
Target Price
$174.90
$24.31
AVG Volume (30 Days)
552.2K
8.3M
Earning Date
02-19-2026
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$707,890,000.00
$20,329,000.00
Revenue This Year
$17.84
N/A
Revenue Next Year
$12.44
$741.42
P/E Ratio
$5,323.01
N/A
Revenue Growth
11.74
N/A
52 Week Low
$102.97
$8.73
52 Week High
$182.52
$23.47

Technical Indicators

Market Signals
Indicator
RGEN
ROIV
Relative Strength Index (RSI) 53.91 56.28
Support Level $161.41 $21.36
Resistance Level $167.65 $22.72
Average True Range (ATR) 4.61 0.72
MACD -0.11 -0.13
Stochastic Oscillator 68.88 32.69

Price Performance

Historical Comparison
RGEN
ROIV

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: